Amphastar Pharmaceuticals is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and proprietary injectable, intranasal, and inhalation products, as well as insulin active pharmaceutical ingredient (API). Its capabilities include characterizing complex molecules, analyzing and synthesizing peptides and proteins, conducting immunogenicity studies, engineering particles, and improving drug delivery through sustained-release technology. The company is able to develop and manufacture a range of dosage formulations, including solutions, emulsions, suspensions, and lyophilized products, as well as products administered via pre-filled syringes, vials, nasal sprays, metered dose inhalers, or MDIs, and dry powder inhalers, or DPIs. Amphastar operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets, and distributes enoxaparin, naloxone, phytonadione, lidocaine, medroxyprogesterone acetate, Primatene Mist, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development.